Skip to main content
. Author manuscript; available in PMC: 2019 Dec 30.
Published in final edited form as: Cancer Chemother Pharmacol. 2009 Aug 7;65(5):817–824. doi: 10.1007/s00280-009-1085-7

Table 3.

Penetration of the platinum analogs into the CNS (CSF standard sampling or brain measured using microdialysis) expressed as a percentage of drug systemic exposure (AUC in plasma UF by standard sampling or vein by microdialysis)

AUC04hCNS:AUC04hBlood(%)

CSF:Plasma UF Brain:Vein

Cisplatin 4.4, 5.4a 1.0, 3.1a
Carboplatin 1.5 (1.4–5.0) 3.1 (3.0–3.1)
Oxaliplatin 0.3 (0.3–0.8) 2.2 (1.4–8.0)

Values represent the median (range)

a

Data from two animals receiving the 10 mg/kg dose